Onco-Summaries: Daily Oncology Updates at a Glance

19/06/2025

Initial patient screening completed in Transgene's Phase 2 trial of TG4050 vaccine in resectable SCCHN (Ref)

• Transgene completed the initial patient screening in the randomized Phase 2 part of its Phase 1/2 TG4050.02/NCT04183166 trial evaluating TG4050 (individualized neoantigen vaccine) mono as an adjuvant Tx of HPV-ve SCCHN

• In Ph1 part of the trial, the vaccine elicited promising outcomes with a 2-yr DFS rate of 100.0%

• Transgene expects to complete randomization of all patients in the Phase 2 part by end-2025, following a second screening of patients conducted after surgery and adjuvant chemo ± radiotherapy

• First Phase 2 immunogenicity data are expected by H2'26, and preliminary efficacy data by H2'27